CVC CAPITAL PARTNERS PLC

How CVC Capital’s stake in ABG fuels a new wave of brand‑backed financing for Aston Martin, redefining risk, return, and strategy for institutional investors.

See how CVC Capital’s first‑half 2026 results beat expectations and why it’s weighing a $500‑$600M sale of Yikang Pharmaceutical, revealing its sharp portfolio‑rebalancing strategy.

CVC Capital Partners eyes sale of China’s Yikang Pharmaceutical, a 1,700‑store online‑to‑offline pharmacy chain, sparking investor interest in the regional healthcare market.

Explore how CVC Capital Partners’ co‑control deal with a Middle‑Eastern sovereign wealth fund will delist a leading rare‑disease pharma, boost R&D, and reshape the market.

See how CVC Capital’s takeover of Malaysia’s AHAM Asset Management drives its dual‑sector strategy, unlocking fintech growth and ESG‑aligned returns.

Discover how CVC Capital Partners’ acquisition of IFF’s food‑ingredients division reshapes private‑equity strategy, ESG goals, and market growth in the ingredient sector.

Discover how CVC Capital Partners is reshaping its portfolio toward European infrastructure, AI‑driven tech, and Asian growth, balancing inflation risks and global opportunities.

Explore how CVC Capital Partners’ micro‑finance pivot and dsm‑firmenich’s resilient consumer‑goods strategy deliver growth, margin stability, and shareholder value in a shifting regulatory landscape.

Teleflex shares jump 8.9% as CVC and GTCR eye a private‑equity takeover, promising restructuring gains, higher cash flow and a potential 12‑15% valuation boost.

Read how CVC Capital Partners’ €1.2 bn backing of ΔΕΗ’s €4 bn equity raise strengthens Greece’s renewable push and boosts investor confidence in the EU decarbonization effort.